Tobramycin eye drops

Tobramycin. Chemical name: O-3-amino-3-deoxy-α-O-glucopyranosyl-(1→6)-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1→4)]-2-deoxy-D-streptamine. Molecular weight: C18H37N5O9

This product is a colorless or almost colorless clear solution.

Drop into the eyelid. Mild and moderate infection: 1-2 drops at a time, once every 4 hours; severe infection: 2 drops at a time, once every hour.

Occasionally, local irritation symptoms may occur, such as burning or swelling of the eyelids, conjunctival erythema, etc.; allergic reactions are rare.

Patients who are allergic to this product or other aminoglycoside antibiotics are contraindicated.

Precautions for children: Since this product has potential nephrotoxicity and ototoxicity, it should be used with caution in children. Precautions for pregnancy and lactation: After eye drops, a small amount of this product is absorbed into the systemic blood circulation. Since a small amount of the absorbed part can pass through the placenta and can also be secreted into breast milk, pregnant women should use it with caution. Lactating women should suspend breastfeeding during the use of this product. Precautions for the elderly: Since this product has potential nephrotoxicity and ototoxicity, it should be used with caution in elderly patients.

1. This product, when used in combination with other aminoglycosides, may increase ototoxicity, nephrotoxicity and neuromuscular blocking effects. Hearing loss may occur, and may progress to deafness after drug discontinuation; hearing loss may recover or be permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). The use of anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product, when used in combination with neuromuscular blockers, may aggravate neuromuscular blocking effects, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or applied locally or systemically in succession, it may increase ototoxicity and nephrotoxicity, and hearing loss may occur.

Seal and store in a cool, dry place.

5ml:15mg

24 months

Chengdu Brilliant Pharmaceutical Co., Ltd.

• Founded in:

  1995-10-10

• Address:

  No. 263, Hexiang 3rd Street, Chengdu Hi-tech Zone

• Tax NO.:

  91510100633104205M

• Registered Funds:

  450 million yuan

• Website:

  Log in to view

• Email:

  Log in to view